» Articles » PMID: 30180151

Association of Vitamin D and Parathyroid Hormone With Barrett's Esophagus

Overview
Specialty Gastroenterology
Date 2018 Sep 5
PMID 30180151
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Esophageal adenocarcinoma has been inversely associated with exposure to ultraviolet radiation. This could be because of vitamin D deficiency or hyperparathyroidism promoting gastroesophageal reflux disease (GERD) and Barrett's esophagus.

Aim: The aim of this study is to determine the association between parathyroid hormone (PTH) and vitamin D deficiency with GERD symptoms, erosive esophagitis, and Barrett's esophagus.

Methods: We assayed banked serum for PTH and total 25-hydroxy vitamin D from a cross-sectional cohort. Logistic regression was performed to estimate the associations of vitamin D deficiency and hyperparathyroidism with GERD symptoms, erosive esophagitis, and Barrett's esophagus.

Results: Sera from 605 men were assayed, including 150 with GERD, 216 with erosive esophagitis, 145 with Barrett's esophagus, and 174 normal subjects. Contrary to our hypothesis, we found a strong inverse association between Barrett's esophagus and hyperparathyroidism (odds ratio=0.516; 95% confidence interval=0.265, 1.01), and a trend toward an inverse association with vitamin D deficiency. We found no association between vitamin D deficiency or hyperparathyroidism with GERD symptoms or erosive esophagitis.

Conclusions: Contrary to our hypothesis, we found an inverse association between serum PTH and Barrett's esophagus. Validation of the finding and the mechanism of that association deserves further study.

References
1.
Tuma S, Mukhopadhyay A . The effect of parathyroid hormone on the esophageal smooth muscle of the opossum. Am J Gastroenterol. 1980; 74(5):415-8. View

2.
Rubenstein J, Morgenstern H, McConell D, Scheiman J, Schoenfeld P, Appelman H . Associations of diabetes mellitus, insulin, leptin, and ghrelin with gastroesophageal reflux and Barrett's esophagus. Gastroenterology. 2013; 145(6):1237-44.e1-5. PMC: 3914630. DOI: 10.1053/j.gastro.2013.08.052. View

3.
Khalili H, Huang E, Jacobson B, Camargo Jr C, Feskanich D, Chan A . Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ. 2012; 344:e372. PMC: 3269660. DOI: 10.1136/bmj.e372. View

4.
Targownik L, Lix L, Leung S, Leslie W . Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2009; 138(3):896-904. DOI: 10.1053/j.gastro.2009.11.014. View

5.
Block G, Hartman A, Naughton D . A reduced dietary questionnaire: development and validation. Epidemiology. 1990; 1(1):58-64. DOI: 10.1097/00001648-199001000-00013. View